NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Obesity and Cardiometabolic Risk in American Indian Youth
With the rising prevalence of obesity among minority youth in the United States (US), there has been a concurrent rise in associated comorbidities such as…
Case Study: Rural Healthcare Inequities
The theme of this edition of LipidSpin addresses disparities in healthcare affecting our rural communities, with a focus on access to specialists treating lipid disorders….
Navigating A Food Desert
Many of us probably cannot imagine not having the means to eat what we want when we want. Every day we decide between something healthy…
Hypertriglyceridemia and the Risk of Cardiovascular Disease and Pancreatitis in a Veteran Population
The Veterans Health Administration (VA) is the nation’s largest integrated health care delivery system serving more than 11 million patients. There recently has been renewed…
Cardiovascular Disease in the Rural American Population
Despite significant improvements in cardiovascular disease (CVD) outcomes and decline in overall CVD deaths, CVD continues to be the leading cause of death in the…
Differences in Statin Metabolism in East Asians
Elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) play a significant role in the development of Coronary Artery Disease (CAD).(1) In clinical trials, reducing LDL-C…
Management of Hypertriglyceridemia in a Patient Considered an Undocumented Immigrant
IntroductionThe management of elevated triglycerides is a means by which the burden of Atherosclerotic Cardiovascular Disease(ASCVD) may be reduced and the complication of pancreatitis may…
Tools for Alleviating Drug Disparities in Lipidology
The armamentarium for lipid-lowering pharmacotherapy is evolving. Though statins remain the cornerstone of treatment, and nearly all statins and ezetimibe are generic, recent and emerging…